Monitoring of cardiac function by serum @entity10020 levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated XXXX and high-dose @entity786 .

@entity1 @entity712 @entity296 @entity5 @entity73 @entity786 @entity10020 @entity348 @entity299 @entity1162 @entity943 @entity1370
OBJECTIVES: Highly differing rates of @entity299 associated with high-dose @entity786 (CY) have been reported, and only one clinical study has been performed on the @entity1370 effects of CY monotherapy following @entity348 ( @entity348 ). @entity1 AND METHODS: We prospectively evaluated the potential @entity1370 effects of conditioning with fractionated @entity348 and high-dose @entity786 ( @entity348 /CY) by serial measurement of serum @entity10020 ( @entity10020 ), assessment of systolic and diastolic echocardiographic parameters and analysis of ventricular repolarisation indices ( @entity1162 and @entity1162 ) in 30 adult @entity1 with haematological @entity5 undergoing haematopoietic stem cell transplantation. RESULTS: There was no evidence of pretreatment @entity299 in any @entity1 . Although @entity10020 was determined serially for a median of 14 d after completion of conditioning, no elevated levels were observed. Echocardiographic parameters did not show any significant change at a median follow-up of 5 months except for one @entity1 with evidence of @entity73 . No significant differences for mean values before and after high-dose CY were noted for ventricular repolarisation indices. Two @entity1 had a significant increase in @entity1162 after CY without any other signs of @entity1370 . @entity712 or @entity943 were not observed. CONCLUSIONS: These data suggest that @entity348 /CY is safe with respect to @entity1370 in @entity1 without pre-existing @entity299 . Hitherto unknown synergistic @entity1370 effects of CY with other cytostatic drugs may constitute the major pathogenic factor of @entity296 after high-dose chemotherapy.
